Statement of Issues released for Elanco’s application to acquire Bayer’s animal health business
Published07 May 2020
The Commerce Commission has published a statement of issues relating to an application from Elanco seeking clearance to acquire Bayer AG’s animal health business in New Zealand.
The Statement of Issues outlines the Commission’s potential competition issues with the acquisition following its initial investigation. The Statement of Issues is not a final decision and does not mean that the Commission intends to decline or clear the merger.
The Commission is seeking submissions from Elanco, Bayer and other interested parties on the issues raised in the Statement of Issues. The Statement of Issues can be found on the case register.
Submissions are due by close of business 21 May 2020, with cross-submissions due by close of business 28 May 2020.
The Commission acknowledges that some interested parties may face a range of challenges due to COVID-19. This may impact their ability to submit in a meaningful way within these timeframes. If you would like to make a submission but face difficulties in doing so within the timeframe, please ensure that you register your interest with the Commission at email@example.com so that we can work with you to accommodate your needs where possible.
The Commission is currently scheduled to make a decision on the application by 3 June 2020. However, this date may be extended.
We will give clearance to a proposed merger if we are satisfied that the merger is unlikely to have the effect of substantially lessening competition in a market.
Further information explaining how the Commission assesses a merger application is available on our website.